You Can Now Get Weight-Loss Drugs Right From Eli Lilly

[ad_1] Eli Lilly started a new online service offering telehealth prescriptions and direct home delivery of its new anti-obesity drug Zepbound, an unusual move into the drug supply chain by…

Walgreens stock plunges after drugstore chain slashes quarterly dividend nearly in half

[ad_1] Shares of Walgreens fell more than 11% on Thursday after the company reported fiscal first-quarter adjusted earnings and revenue that topped expectations, but cut its quarterly dividend nearly in…

The Future Is Bright if You Know Where to Look

[ad_1] A burst of advances in artificial intelligence, medicine and elsewhere promise a better life down the road. [ad_2] Source link

Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years

[ad_1] Artur Widak | Nurphoto | Getty Images Shares of Moderna closed more than 13% higher on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker…

Biden administration’s Medicare drug price negotiations will face major tests in 2024

[ad_1] Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna…

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

[ad_1] In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how…

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology.  RayzeBio…

How to Ride the Biotech Roller Coaster

[ad_1] With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs. But investing…

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

[ad_1] AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business. The upfront cash…